[Candida infections in infancy and early childhood]. 1998

R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
Kinderklinik der Technischen Universität Dresden.

Candida infections in infancy can manifest themselves as skin, mucosal or systemic candidiasis. Eighty to nintey percent of all candida infections in this age group are caused by Candida albicans. Whereas in neonates, infections mostly occur sub partu, in older children predisposing underlying diseases get an increasing etiological importance. The diagnosis is based on microscopic and cultural detection of yeast as well as on the course of the titers of Candida antigen and antibodies. For topical antifungal treatment of skin and mucosa infections, different preparations of the polyenes nystatin and amphotericin B have been proven to be most effective. In systemic candidiasis the combination of amphotericin B and 5-flucytosin is the treatment of choice. In view of the potential severe side effects of this combination therapy, fluconazol as a sole treatment represents an effective alternative. Prophylaxis against Candida infections comprises sticking to hygienic regimes, mycological surveillance of risk groups and oral application of antimycotics.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005437 Flucytosine A fluorinated cytosine analog that is used as an antifungal agent. 5-Fluorocytosine,Alcobon,Ancobon,Ancotil
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
February 2013, The European respiratory journal,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
October 1988, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
February 1988, Orvosi hetilap,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
January 1967, Kinderarztliche Praxis,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
March 2018, Pediatric dentistry,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
January 1963, The New England journal of medicine,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
August 1974, Harefuah,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
January 1993, Medizinische Monatsschrift fur Pharmazeuten,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
January 1996, Klinische Padiatrie,
R Schwarze, and C Seebacher, and R Blaschke-Hellmessen
May 1954, New York state journal of medicine,
Copied contents to your clipboard!